İ. Halil ÖZEROL, Ana AGEITOS, James E. TALMADGE, Mustafa ŞENOL

The investigation of the responses to phytohemagglutinin in the patients of non-Hodgkin's lymphoma who were candidates for high dose chemotherapy, autologous bone marrow or peripheral stem cell transplantation

Fitohemaglutinin (PHA), genellikle bir T lenfosit mitojenidir. CD4+ helper/inducer T lenfositlerine, CD8' suppressor/cytotoxic T lenfositlerine göre daha fazla stimulator etki yapar. Bu çalışmada, biz normal periferik kan lökositleri (PBL) ile otolog kemik iliği (BM) ve granulosit-monosit koloni stîmulan faktör (GM-CSF) ile mobilize edilmiş periferik stem cell (PSC) ürünlerinin PHA 'e verdikleri mitojenik cevapların farklı olup olmadığını araştırdık. Non-Hodgkin lenfomalı 24 hastadan kemik iliği ve periferik stem cell ürünleri toplandı ve IL-2 ile 5 gün kültür yapılmadan önce ve yapıldıktan sonra PHA hücre proliferasyon cevabı incelendi. Hem PSC hem de BM hücrelerinin PHA proliferatif cevapları anlamlı şekilde normal PBL 'den düşüktü (p

Yüksek doz kemoterapi, otolog kemik iliği veya periferik stem cell transplantasyonu yapılacak non-Hodgkin lenfomalı hastalarda fitohemaglutinin'e cevabın araştırılması

Phytohemagglutinin (PHA) is principally a T lymphocyte mitogen, producing a greater stimulatory effect* on CD4+ helper/inducer T lymphocytes than on CD8+ suppressor/cytotoxic T cells. In this study, investigated if there are differences in the mitogenic response to PHA between autologous bone marrow " (BM) and granulocyte-monocyte colony stimulating factor (GM-CSF)-mobilized peripheral stem cell (PSC) products as well as to normal peripheral blood leukocytes (PBL). BM and PSC products from 24 patients with non-Hodgkin's lymphoma (NHL) were collected and assays of cell proliferation in response to PHA were performed both before and following 5 days co-incubation with IL^2. The proliferative response to PHA by cells from both PSC and BM products were significantly lower than normal PBL (p

PDF

___

1.Cruise JM, Lewis RE. Illustrated Dictionary ofImmunology. New York. CRC press. 1995:206.
2.Oppenheim JJ, Ruscetti FW, Faltynek C. Cytockines. In:Stites DP, Terr AI, Parslow TG, (eds). Basic and ClinicalImmunology. 8th ed. Norwalk. Appleton and Lange.1994:105-23.
3.Gibson FM, Malkovska V, Myint AA, et al. Mechanism ofsuppression of normal hematopoietic activity bylymphokine-activated killer cells and their products. ExpHematol 1991; 19:659-73.
4.Lum LG. The kinetics of immune reconstitution after humanmarrow transplantation. Blood 1987; 69:369-80.
5.Lum LG, Ueda M. Immunodeficiency and the role ofsuppressor cells after human bone marrow transplantation.Clin Immunol Immunopathol 1992; 63:103-9.
6.Gottschalk LR, Bray RA, Kaizer H, Gebel HM. Twopopulations of CD56 (Leu-19)+ /CD16+ cells in bonemarrow transplant recipients. Bone Marrow Transplant1990; 5:259-64.
7.Talmadge JE, Reed EC, Kessinger A, et al. Immunologicattributes of cytockine mobilized peripheral blood stem cellsand recovery following transplantation in non-Hodgkin’slymphoma patients. Bone Marrow Transplant 1996; 17:101-9.
8.Smith KA. Interleukin-2: Inception, impact, andimplications. Science 1988; 240:1169-76.
9.Gratwohl A, Hermans J, Baldomero H. Hematopoieticprecursor cell transplantation in Europa: Activity in 1994.Report from the European group for Blood and MarrowTransplantation (EBMT). Bone Marrow Transplant 1996;17:137-48.
10.Goldman JM. Peripheral blood stem cells for allografting.Blood 1995; 85: 1413-6.
11.Korbling M, Juttner C, Henon P, Kessinger A. Autologousblood stem cell versus bone marrow transplantation. BoneMarrow Transplant 1992; 10 (Suppl 1): 144-8.
12.Bell AJ, Figes A, Oscier DG, Hamblin TJ. Peripheral bloodstem cell autografts in the treatment of lymphoidmalignancies: initial experience in three patients. Br JHaematol 1987; 66: 63-8.
13.Gribben JG, Freedman AS, Neuberg D, et al. Immunologicpurging of marrow assessed by PCR before autologous bonemarrow transplantation for B-cell lymphoma. N Engl J Med1991; 325: 1525-33.
14.Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, SmithKA, Ritz J. Functional consequences of interleukin-2receptor expression on resting human lymphocytes:Identification of a novel natural killer cell subset with highaffinity receptors. J Exp Med 1990; 171:1509-26.
15.Farace F, Angevin E, Dietrich P-R, et al. Low-dose IL-2treatment: Activation of discrete T- and NK-cell sub-populations in vivo. Int J Cancer 1995; 62:523-8.
16.Thatcher N, Gasiunas N, Crowther D. Lymphocyte functionin the blood of patients with untreated non-Hodgkinlymphoma: Influence of stage and pathology. Med PedOncol 1977; 3:311-21.
17.Noguchi S, Bukowski R, Deodhar S, Hewlett JS. T and Blymphocytes in non-Hodgkin’s lymphoma. Cancer 1976;23:89-98.
18.Talmadge JE. The combination of stem cell transplantationand immunotherapy: Future potential. In Vivo 1994;8(5):675-90